Chimeric vaccines
AssigneeThe Johns Hopkins University
InventorsThomas August, Ernesto Marques, JR.
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Johns Hopkins University
InventorsThomas August, Ernesto Marques, JR.
Estimating the term…
The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.
A DNA vaccine comprising a chimeric vector encoding a fusion protein which comprises an antigen domain comprising at least one epitope and a trafficking domain and a pharmaceutical carrier.
A DNA vaccine comprising a chimeric vector encoding a fusion protein which comprises a Gag polypeptide fused in frame with a mammalian cellular polypeptide and a pharmaceutical carrier.
A method for generating an immune response in an animal to an antigen, comprising:
A method for eliciting an immune response to an antigen, comprising administering to an animal a cell comprising a vector comprising a nucleic acid molecule encoding a chimeric protein comprising an antigen domain comprising at least one epitope, and a trafficking domain.
Dependencies are inferred from the claim text.